FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:359-361 January 23, 2003 Number 4 Next

Inhibition of Tumor Necrosis Factor and Ankylosing Spondylitis

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Gorman, J. D. Related Article by Gorman, J. D. PubMed Citation

To the Editor: In a recent multicenter trial, Gorman et al. (May 2 issue)¹ found that 80 percent of patients with active ankylosing spondylitis had a favorable response to etanercept. Equivalent results are obtained with infliximab.² Data on uveitis are still lacking. We report a case of severe uveitis in a 45-year-old man that improved with infliximab.

In 1986, the patient was given a diagnosis of HLA-B27–positive ankylosing spondylitis. Since 1993, he had had recurrent bilateral anterior uveitis, leading to functional blindness of the right eye despite the use of antiinflammatory drugs, including corticosteroids. When he was seen in May . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.